Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study
Open Access
- 1 October 2014
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 7 (5) , 620-625
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Sunitinib in solid tumorsExpert Opinion on Investigational Drugs, 2009
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Kinase Mutations and Imatinib Mesylate Response for 64 Taiwanese with Advanced GIST: Preliminary Experience from Chang Gung Memorial HospitalAnnals of Surgical Oncology, 2006
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Gastrointestinal stromal tumors: From a surgical to a molecular approachInternational Journal of Cancer, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998